Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, SVY

Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022


Live Conference Call and Webcast at 8:30 AM ET

PALO ALTO, Calif., Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV.

The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com. To participate in the live call by phone, dial (866) 374-5140 (U.S.) or (404) 400-0571 (International) and enter PIN 79797687#. The webcast will be archived and available for replay for at least 90 days after the event.

About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
[email protected]    

Media:
Sarah Mathieson
SVP, Corporate Affairs
[email protected] 

 

SOURCE Eiger BioPharmaceuticals, Inc.


These press releases may also interest you

at 13:50
Phenom Releases Massive Wave of HR Tech Innovation: Talent Experience Engine, Next-GenAI Agents, New Platform Experiences, and Updates for Talent Acquisition and Talent Management
During its IAMPHENOM 2024 Product Innovation Keynote, Phenom announced a massive wave of platform innovations ? including Talent Experience Engine, X+ Agents, Talent Marketer Experience and Talent Leader Experience. These innovations deliver unique...

at 13:15
Biz Apps Partner Summit for Microsoft Ecosystem to Deliver FY 25 Insights
Dynamics Communities and Community Summit North America, in collaboration with Microsoft, are introducing the Biz Apps Partner Summit to run July 24-25, 2024, in Bellevue, Washington delivering a 24-hour immersion into FY 25 priorities, opportunities...

at 13:13
E-Textile Market Size to Grow USD 5238.3 Million by 2029 at a CAGR of 8% | Valuates Reports
E-Textile Market is Segmented by Type (Passive Electronic Textiles, Active Electronic Textiles, Ultra-Electronic Textiles), by Application (Military Uses, Civil Uses, Healthcare Uses). The Global E-Textile Market size is expected to reach USD 5238.3...

at 13:05
Dr. J. Mark Tuthill Joins Gestalt Diagnostics' Strategic Advisory Board
Gestalt Diagnostics has added healthcare industry expert, Dr. J. Mark Tuthill, to serve on Gestalt's Advisory Board. He will be joining Gestalt's distinguished Advisory Board of pathologists contributing to oversight and active input of development...

at 12:57
Hinkal Closes Strategic Funding Round to Advance Discreet Trading and Position Liquidation
Hinkal, a multi-chain privacy layer for confidential decentralized finance (DeFi) transactions, today announced a $1.4 million strategic funding round led by SALT Fund, with participation from Draper Associates, SNZ and Peer VC. Additionally, Tal...

at 12:45
Sogolytics Study Examines Patient Experience Gaps in Telehealth Adoption
Leading research and experience management firm Sogolytics has released an original study examining the telehealth landscape, highlighting its achievements and challenges in providing positive experiences for patients. "It's critical for providers...

More news about Science and technology...


News published on and distributed by: